This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F68378050%3A_____%2F03%3A23033174%21RIV%2F2004%2FAV0%2FA23004%2FN/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F68378050%3A_____%2F03%3A23033174%21RIV%2F2004%2FAV0%2FA23004%2FN
rdf:type
skos:Concept n17:Vysledek
dcterms:description
It has been found previously that IL-2, IFNgamma and GM-CSF were capable of reducing the recurrence rate of HPV 16-associated tumours in mice with SMRTD. We were interested whether the therapeutic effect of the surgery and adjuvant cytokine treatment was accompanied by cytolytic activity of spleen cells and whether the activity of the spleen cells was different in mice that had rejected tumour residua after surgery and adjuvant therapy with cytokines (tumour regressors) as compared to those that had not rejected the tumour residua (tumour progressors). We have examined the cytolytic activity of spleen cells from MHC class I+ TC-1 tumour regressors and progressors after treatment of TC-1 SMRTD with GM-CSF, and the activity of spleen cells from MHC class I- MK16 tumour regressors and progressors after treatment of MK16 SMRTD with IL-2 and IFNgamma. The cytolytic activity of spleen cells from mice with SMRTD allowed to react with MHC class I+, MHC class I-, NK-sensitive and NK-resistant targets is compat It has been found previously that IL-2, IFNgamma and GM-CSF were capable of reducing the recurrence rate of HPV 16-associated tumours in mice with SMRTD. We were interested whether the therapeutic effect of the surgery and adjuvant cytokine treatment was accompanied by cytolytic activity of spleen cells and whether the activity of the spleen cells was different in mice that had rejected tumour residua after surgery and adjuvant therapy with cytokines (tumour regressors) as compared to those that had not rejected the tumour residua (tumour progressors). We have examined the cytolytic activity of spleen cells from MHC class I+ TC-1 tumour regressors and progressors after treatment of TC-1 SMRTD with GM-CSF, and the activity of spleen cells from MHC class I- MK16 tumour regressors and progressors after treatment of MK16 SMRTD with IL-2 and IFNgamma. The cytolytic activity of spleen cells from mice with SMRTD allowed to react with MHC class I+, MHC class I-, NK-sensitive and NK-resistant targets is compat
dcterms:title
Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors.
skos:prefLabel
Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors.
skos:notation
RIV/68378050:_____/03:23033174!RIV/2004/AV0/A23004/N
n4:strany
217;222
n4:aktivita
n9:Z
n4:aktivity
Z(AV0Z5052915)
n4:cisloPeriodika
49
n4:dodaniDat
n12:2004
n4:domaciTvurceVysledku
n6:1572830 n6:4531140 n6:6215319 n6:9414185 n6:1723758
n4:druhVysledku
n13:J
n4:duvernostUdaju
n8:S
n4:entitaPredkladatele
n10:predkladatel
n4:idSjednocenehoVysledku
597512
n4:idVysledku
RIV/68378050:_____/03:23033174
n4:jazykVysledku
n16:eng
n4:klicovaSlova
HPV16; gene therapy; IL-2
n4:klicoveSlovo
n5:HPV16 n5:IL-2 n5:gene%20therapy
n4:kodStatuVydavatele
CZ - Česká republika
n4:kontrolniKodProRIV
[CF6EEEB0767A]
n4:nazevZdroje
Folia Biologica
n4:obor
n14:EB
n4:pocetDomacichTvurcuVysledku
5
n4:pocetTvurcuVysledku
6
n4:pocetUcastnikuAkce
0
n4:pocetZahranicnichUcastnikuAkce
0
n4:rokUplatneniVysledku
n12:2003
n4:svazekPeriodika
2003
n4:tvurceVysledku
Vonka, V. Mikyšková, Romana Bieblová, Jana Jandlová, Táňa Bubeník, Jan Indrová, Marie
n4:zamer
n15:AV0Z5052915
s:issn
0015-5500
s:numberOfPages
5